New registry to monitor Real-World impact of NMOSD treatments
NCT ID NCT05966467
First seen Jan 07, 2026 · Last updated May 02, 2026 · Updated 16 times
Summary
This long-term observational registry follows 122 adults with AQP4+ neuromyelitis optica spectrum disorder (NMOSD) who are already taking Alexion C5 inhibitor medications (eculizumab or ravulizumab) to prevent relapses. The study collects data on relapse rates, safety, quality of life, and patient-reported outcomes to understand how these treatments work in everyday practice. No new drugs are given; participants continue their prescribed therapy while researchers observe real-world results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact
-
Clinical Trial Site
RECRUITINGColumbus, Ohio, 43215, United States
Contact
-
Clinical Trial Site
RECRUITINGPlano, Texas, 75024, United States
Contact
-
Clinical Trial Site
RECRUITINGMilwaukee, Wisconsin, 53215, United States
Contact
-
Clinical Trial Site
RECRUITINGBuenos Aires, Argentina
-
Clinical Trial Site
NOT_YET_RECRUITINGBuenos Aires, Argentina
-
Clinical Trial Site
RECRUITINGBuenos Aires, Argentina
-
Clinical Trial Site
RECRUITINGBuenos Aires, Argentina
Contact
Contact
Contact
Contact
-
Clinical Trial Site
RECRUITINGBurnaby, British Columbia, Canada
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGBeijing, China
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGGuangzhou, China
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGHenan, China
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGShanghai, China
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGSichuan, China
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGWuhan, China
Contact
-
Clinical Trial Site
RECRUITINGDresden, Germany
Contact
-
Clinical Trial Site
RECRUITINGEssen, Germany
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGMünchen, Germany
Contact
-
Clinical Trial Site
RECRUITINGNaples, Italy
Contact
-
Clinical Trial Site
RECRUITINGFukuoka, Japan
Contact
-
Clinical Trial Site
RECRUITINGKawasaki, Japan
Contact
-
Clinical Trial Site
RECRUITINGMiyagi, Japan
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGTokyo, Japan
Contact
-
Clinical Trial Site
RECRUITINGDaejeon, South Korea
Contact
-
Clinical Trial Site
RECRUITINGGyeonggi-do, South Korea
Contact
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
Contact
Contact
Contact
Contact
Contact
Contact
-
Research Site
RECRUITINGBoston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.